MTDs developed for AD have modified two or more of known targets (cholinesterases, MAOs, acetylcholine receptors, serotonin receptors) or have properties thought to retard disease progression, such as metal chelation, antioxidant or anti-inflammatory activity, or prevention of Aβ or tau aggregation. The gene discussed is BCHE; the disease is Alzheimer disease.